secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2021-10-04T23:59:59+00:00
Accession:  0001104659-21-122499
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure appoints Anne Borgman, M.D., and Ellen Feigal, M.D. to board
---------------------------------------------------------------------

- Borgman joins as Class I director; Feigal as Class II director; both deemed independent.
- Borgman serves on Nominating and Governance Committee; Feigal on Compensation Committee.
- Borgman is VP at Jazz Pharmaceuticals; Feigal is Partner at NDA Partners.
- Appointments follow resignation of Stella Xu, Ph.D. from the board.
- New directors bring oncology and biopharma development expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465921122499/0001104659-21-122499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465921122499/tm2129158d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-122499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer